Core Insights - Restart Life Sciences Corp. has successfully acquired Holy Crap Foods Inc. and entered a collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research (RCFTR) to enhance its product development in functional wellness [1][2]. Group 1: Collaboration and Research Objectives - The partnership with RCFTR aims to advance functional foods that support brain health, cognitive wellness, and gut health, focusing on validating product formulations and optimizing ingredient functionality [2][6]. - The research collaboration will generate scientific insights to support the development of the company's functional wellness portfolio, including brain health and digestive health products [7][9]. - The project may assess ingredient behavior in various formulations, including sensory characteristics and nutrient retention, to guide future optimization efforts [8][9]. Group 2: Product Development and Brand Expansion - Restart Life Sciences has introduced several health brands, including BrainQ™, BrainBalls™, and Holy Crap™, expanding its functional wellness platform beyond cognitive health into gut health [4][5]. - The integration of Holy Crap™ products into the portfolio is expected to enhance the company's offerings in gut health, which is increasingly linked to overall well-being [5][6]. - The collaboration with RCFTR will help establish a scientific framework for ingredient evaluation and formulation performance across all product lines [6][10]. Group 3: Company Background and Future Directions - Restart Life Sciences Corp. is a Canadian-based life sciences company focused on advancing functional foods and wellness products [14]. - The RCFTR is a state-of-the-art facility dedicated to food quality and innovation, providing essential support for the company's research and development efforts [11]. - The collaboration is expected to yield high-level scientific observations and recommendations that will support ongoing product development and quality assessment initiatives [10].

As filed with the Securities and Exchange Commission on January 29, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LITTLE WEST HOLDINGS INC. (Exact name of registrant as specified in its charter) | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 426 E 58 Street Los Angeles, California ...

Core Insights - Celsius Holdings (CELH) is positioning itself as a leader in the modern energy category by expanding its product portfolio beyond traditional energy drinks, including the acquisition of Alani Nu and the launch of CELSIUS HYDRATION [1][8] - The company is experiencing strong international growth of 41% and holds a 16.2% dollar share in the U.S. energy drink category [3][8] - CELH's stock has surged 75% year to date, significantly outperforming the industry average [7] Product Expansion - The acquisition of Alani Nu, which appeals to female consumers, complements CELH's core offerings and broadens its consumer base [1] - CELH has entered the hydration market with CELSIUS HYDRATION, targeting the $1.4 billion hydration powder market [1] - New flavors and multipack expansions have contributed to over 50% of sales in certain channels [2] Market Position and Competitors - CELH's competitors include PepsiCo (PEP) and The Coca-Cola Company (KO), both of which are transforming their portfolios to meet consumer demands for health and functionality [4][5][6] - PepsiCo is focusing on zero-sugar variants and wellness-driven products, while Coca-Cola is prioritizing bold product launches and integrating advanced digital marketing [5][6] Financial Performance - Despite a 7% revenue decline in Q1 2025, CELH remains optimistic about future growth due to a strong prior-year comparison and ongoing product innovation [3][8] - The company has a forward price-to-earnings ratio of 46.19X, significantly higher than the industry average of 15.91X [9] - The Zacks Consensus Estimate indicates year-over-year EPS growth of 17.1% for 2025 and 41.6% for 2026, with stable estimates over the past week [10]

Core Insights - ArcStone Securities and Investments Corp. serves as the exclusive financial advisor to Mangoceuticals Inc. in its acquisition of Smokeless Technology Corp., marking Mangoceuticals' entry into the high-growth oral stimulant pouch sector [1][2][3] - The acquisition enhances Mangoceuticals' capabilities in the consumer-packaged goods sector, targeting various demographics including athletes and Gen Z consumers seeking healthier alternatives [3][6] - The transaction is expected to position Mangoceuticals as a leader in the next-generation health and wellness delivery market, leveraging Smokeless Tech's intellectual property and formulations [6][7] Company Overview - Mangoceuticals Inc. is focused on launching high-impact pouches and aims to disrupt traditional wellness delivery methods with "better-for-you" energy solutions [6][7] - The company is set to benefit from the expertise of Tim Corkum, a veteran from Philip Morris International, who will lead the new Pouch Division [4][5] - The acquisition positions Mangoceuticals as one of the few public companies in the functional wellness and oral delivery market, appealing to both institutional and retail investors [8] Strategic Implications - The deal signifies a transformational step for Mangoceuticals, aligning with the trend towards on-the-go, clinically informed wellness solutions [7] - ArcStone's role underscores its expertise in cross-border M&A, particularly in the health and wellness sectors, enhancing its reputation in the financial advisory landscape [3][9] - The combined entity will focus on sourcing disruptive ingredients and proprietary formulations, aiming to lead in the wellness delivery category [6][7]